[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"natural-history\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:natural-history":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100568375","epithelioid-haemangioendothelioma-observational-study-100568375",false,"NCT06680401","Epithelioid Haemangioendothelioma Observational Study","The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets","Inclusion Criteria:\n\n* Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen\n* Signed informed consent\n* Adequate patient compliance to treatment or follow up\n* No age limit\n\nExclusion Criteria:\n\n* Impossibility to ensure adequate compliance","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","OBSERVATIONAL","The EHE observational study was developed to obtain a high number of datas such as clinical presentation, natural history, and treatment outcomes, cto identificate cytokines and hormones as biomarkers and generate patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets",[24,25,26],"Clinical Presentation","Natural History","Treatment Outcomes","RECRUITING","2026-03-27",{"date":30,"type":31},"2026-04-01","ACTUAL",{"date":33,"type":31},"2021-02-25",{"date":35,"type":20},"2028-12",{"name":37,"class":38},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":53,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":5},"100544279","phenotypes-in-non-ambulant-duchenne-muscular-dystrophy-100544279","NCT06366815","phenotypeS in Non Ambulant Duchenne Muscular Dystrophy","Characterizing Phenothypes in Non Ambulant Duchenne Muscular Dystrophy","GUP21003","Inclusion Criteria:\n\n* Children with genetically confirmed diagnosis of Duchenne Muscular Dystrophy will be included in the study. We will include all Duchenne Muscular Dystrophy boys who have lost the ability to walk independently.\n* All patients in whom consent can be obtained will be enrolled with no exclusion criteria.\n\nExclusion Criteria:\n\n* Patients lacking genetic confirmation of Duchenne Muscular Dystrophy\n* Patients still able to walk for more than 10 meters.","MALE","8 Years","35 Years",{"count":52,"type":20},250,"2 Years","The aims of the study are to prospectively collect information on several aspects of function in non-ambulant DMD patients by using a structured battery of tests including motor, respiratory and cardiac function",[56,25,57],"Duchenne Muscular Dystrophy","Motor Function; Retardation","2024-10-03",{"date":60,"type":31},"2024-10-04",{"date":62,"type":31},"2022-08-30",{"date":64,"type":20},"2025-12-30",{"name":66,"class":38},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]